Esperion Therapeutis.Inc. buy WatchMen
Start price
14.10.23
/
40%
€0.82
Target price
14.10.24
€10.00
Performance (%)
141.90%
Price
09.05.24
€1.97
Summary
This prediction is currently active. With a performance of 141.90% the BUY prediction by WatchMen is a big success. This prediction currently runs until 14.10.24. The prediction end date can be changed by WatchMen at any time. WatchMen has 40% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Esperion Therapeutis.Inc. | 2.351% | 2.351% |
| iShares Core DAX® | 3.178% | 0.980% |
| iShares Nasdaq 100 | 2.972% | 0.925% |
| iShares Nikkei 225® | 0.545% | -4.556% |
| iShares S&P 500 | 2.367% | 0.833% |
Comments by WatchMen for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Buy Esperion Therapeutis.Inc.
Kursziel gesetzt auf 10,0